HCPLive

ADHD 
The MD Magazine ADHD condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Prenatal Antidepressant Exposure Not Linked to Autism, ADHD
Researchers from Massachusetts General Hospital who analyzed medical records from three healthcare systems in their state have found no evidence to indicate that prenatal exposure to antidepressants increases the risk for autism and related disorders or for ADHD.
The FDA has approved Tris Pharma's extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older.
Rates of attention deficit hyperactivity disorder (ADHD) drop as elevation increases, according to findings published in the Journal of Attention Disorders.
Study results published in the July-August 2015 issue of the Journal of the American Board of Family Medicine suggest a potential association between maternal chemical intolerance and a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in their offspring.
Compared to healthy individuals, ADHD patients are 2 times more likely to die prematurely – and the risk is higher in women and girls.
In contrast to recent studies linking patients who reside in higher elevations with increased rates of depression and suicide, a new study suggests that the prevalence of attention-deficit hyperactivity disorder appears to decrease as altitude increases.
Lisdexamfetamine dimesylate, a medication approved for ADHD treatment, was assessed for its efficacy in managing binge eating disorder. In some doses, this approach was effective in 4-week binge eating cessation.
The brains of children and adolescents with attention deficit hyperactivity disorder (ADHD) are slower to develop some key connections, according to a study published in the Proceedings of the National Academy of Sciences.
Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$